These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 31461087

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Relugolix for the treatment of uterine fibroids.
    Rocca ML, Palumbo AR, Lico D, Fiorenza A, Bitonti G, D'Agostino S, Gallo C, Di Carlo C, Zullo F, Venturella R.
    Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
    [Abstract] [Full Text] [Related]

  • 3. Relugolix: First Global Approval.
    Markham A.
    Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
    [Abstract] [Full Text] [Related]

  • 4. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H.
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [Abstract] [Full Text] [Related]

  • 5. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
    Kawahara N, Kawaguchi R, Yamamoto K, Nishikawa K, Matsuoka M, Maehana T, Fukui Y, Yamanaka S, Sugimoto S, Iwai K, Yamada Y, Kurakami H, Hirata T, Takashima R, Suzuki S, Asada K, Kasahara M, Kimura F.
    Trials; 2024 Jan 19; 25(1):68. PubMed ID: 38243317
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
    Kitade M, Kumakiri J, Kobori H, Murakami K.
    Trials; 2024 May 24; 25(1):343. PubMed ID: 38790029
    [Abstract] [Full Text] [Related]

  • 9. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA, Al-Hendy A, Lukes AS, Madueke-Laveaux OS, Zhu E, Proehl S, Schulmann T, Marsh EE.
    Am J Obstet Gynecol; 2024 Feb 24; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [Abstract] [Full Text] [Related]

  • 10. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.
    Nakata D, Masaki T, Tanaka A, Yoshimatsu M, Akinaga Y, Asada M, Sasada R, Takeyama M, Miwa K, Watanabe T, Kusaka M.
    Eur J Pharmacol; 2014 Jan 15; 723():167-74. PubMed ID: 24333551
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A, Lukes AS, Poindexter AN, Venturella R, Villarroel C, Critchley HOD, Li Y, McKain L, Arjona Ferreira JC, Langenberg AGM, Wagman RB, Stewart EA.
    N Engl J Med; 2021 Feb 18; 384(7):630-642. PubMed ID: 33596357
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY.
    Drugs; 2022 Oct 18; 82(15):1549-1556. PubMed ID: 36331779
    [Abstract] [Full Text] [Related]

  • 15. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
    Dababou S, Garzon S, Laganà AS, Ferrero S, Evangelisti G, Noventa M, D'Alterio MN, Palomba S, Uccella S, Franchi M, Barra F.
    Expert Opin Investig Drugs; 2021 Sep 18; 30(9):903-911. PubMed ID: 34278887
    [Abstract] [Full Text] [Related]

  • 16. A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy.
    Sasamori Y, Takehara K, Terashima T, Onodera T, Yatsuki K, Nakagawa I, Takahashi Y, Nishida H, Ichinose T, Hiraike H, Nagasaka K.
    BMC Womens Health; 2021 Aug 19; 21(1):306. PubMed ID: 34412607
    [Abstract] [Full Text] [Related]

  • 17. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA, Lukes AS, Venturella R, Arjona Ferreira JC, Li Y, Hunsche E, Wagman RB, Al-Hendy A.
    Obstet Gynecol; 2022 Jun 01; 139(6):1070-1081. PubMed ID: 35675604
    [Abstract] [Full Text] [Related]

  • 18. Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.
    Evangelisti G, Barra F, Perrone U, Di Donato N, Bogliolo S, Ceccaroni M, Ferrero S.
    Expert Opin Drug Metab Toxicol; 2022 Jun 01; 18(7-8):441-457. PubMed ID: 35968602
    [Abstract] [Full Text] [Related]

  • 19. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
    Barra F, Vitale SG, Seca M, Scala C, Leone Roberti Maggiore U, Cianci A, Ferrero S.
    Expert Opin Pharmacother; 2020 Aug 01; 21(12):1419-1430. PubMed ID: 32401547
    [Abstract] [Full Text] [Related]

  • 20. Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study.
    Muzii L, Galati G, Mercurio A, Olivieri C, Scarcella L, Azenkoud I, Tripodi R, Vignali M, Angioni S, Maiorana A.
    Sci Rep; 2024 Sep 28; 14(1):22481. PubMed ID: 39341875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.